Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2010

View Archived Issues

Medivir identifies NS5B polymerase inhibitors for HCV infection

HIV-targeting gene therapy shows prolonged viremia control in phase I/II trial

HCV RNA synthesis inhibitor ATI-0810 exhibits favorable safety and pharmacokinetics in vivo

Novel focal adhesion kinase inhibitors discovered at AstraZeneca

Roche identifies new inhibitors of Bruton tyrosine kinase BTK

Takeda discloses new renin inhibitors for hypertension

Hutchison MediPharma presents novel epidermal growth factor receptor inhibitors

Phase III NOV-002 trial in NSCLC fails to meet primary endpoint

Enzon treats first pediatric cancer patient in phase I PEG-SN38 trial

New fusion inhibitor shows potent antiviral activity in wild-type and RTI-resistant HIV strains

DIVA 01 trial data indicate good penetration of raltegravir in genital tract of HIV-infected women

HSP90 inhibitor STA-9090 targets oncogenic functions of Wilms tumor protein in AML cells

FDA recommends approval of rifaximin for management of hepatic encephalopathy

Eisai launches Revovir in the Philippines for chronic hepatitis B

FDA accepts Arena Pharmaceuticals' lorcaserin NDA for filing

Basilea enters into global partnership with Astellas for isavuconazole

Five Prime Therapeutics reports milestone for immunology-related therapeutic program

Shire receives FDA fast track designation for Replagal

FDA approves Prevnar 13 for prevention of pneumococcal disease in infants and children

Evotec and Cubist extend and expand research agreement

GSK criticizes Senate Committee on Finance's report on Avandia

U.K. approval granted for HealthLinx's OvPlex trial in ovarian cancer

Kyowa Hakko Kirin submits NDA in Japan for Abstral in breakthrough cancer pain

Cleveland BioLabs responds to Department of Defense RFP for CBLB-502

Anadys reports preliminary phase II results on ANA-598/SOC therapy for hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...